Hallucinogen Use Disorder: Symptoms and Diagnostic Status

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Hallucinogen use disorder is a clinical diagnosis describing a problematic pattern of use associated with impaired control, harmful consequences, or substantial disruption of everyday life. In the DSM-5-TR, the relevant diagnoses include other hallucinogen use disorder and phencyclidine use disorder, each with substance-specific diagnostic rules. The WHO ICD-11 recognizes harmful hallucinogen use and hallucinogen dependence as distinct clinical categories. An intense psychedelic experience, an isolated adverse reaction, frequent use, tolerance, and a persistent visual disturbance each require their own assessment; none by itself establishes a use disorder. The diagnostic task is to establish the substance involved, its temporal relationship to symptoms, the pattern of use, and clinically meaningful impairment. American Psychiatric Association and WHO provide the classification frameworks.

What Is Hallucinogen Use Disorder?

The term hallucinogen use disorder refers to a sustained, clinically problematic relationship with a hallucinogenic substance. Hallucinogens comprise chemically and pharmacologically diverse drugs, so the term spans experiences and risks that cannot be explained by a single mechanism. In clinical language, a disorder is identified through a consistent pattern of behavioral and functional consequences, evaluated against formal criteria and the person's circumstances. A person may have used a substance once and experienced severe intoxication without meeting criteria for a persistent use disorder. Another person may experience repeated, difficult-to-control use that interferes with obligations, relationships, or safety even if withdrawal never occurs. DSM-5-TR clinical criteria summarized by Johns Hopkins.

People may encounter the phrase psychedelic addiction online as a broad description of unwanted use, but clinical classification is more precise. It asks which substance was taken, whether its effects meet the relevant diagnostic category, what objectively changed in daily functioning, and which other conditions explain the presentation. A clinical assessment also takes into account the patient's goals, cultural context, use setting, psychiatric history, concurrent medications, and other substance exposures. The resulting formulation can identify a disorder, a single harmful episode, an acute syndrome, another mental disorder, or a pattern that warrants education and monitoring without establishing a diagnosis.

What counts as a hallucinogen?

Classical serotonergic psychedelics include lysergic acid diethylamide (LSD), psilocybin-containing mushrooms, mescaline, and dimethyltryptamine (DMT). These substances have prominent effects on serotonin 5-HT2A signaling and can produce altered visual processing, unusual associations, changes in time perception, intensified emotions, and altered self-experience. Their acute effects differ across compounds, preparations, individual sensitivity, and setting. NIDA's overview provides an official account of psychedelic and dissociative drugs; Nichols' pharmacological review describes classic psychedelic mechanisms.

The broad survey and everyday category hallucinogens may additionally include phencyclidine (PCP), ketamine, MDMA, salvia, and other drugs that primarily act through dissociative, entactogenic, or mixed mechanisms. These substances vary dramatically in reinforcing effects, toxicity, and diagnostic placement. In particular, the DSM distinguishes PCP use disorder from other hallucinogen use disorder, while ketamine-related misuse requires careful substance identification and clinical coding rather than automatic treatment as classic psychedelic dependence. The scope of this article is the shared question of hallucinogen-related diagnosis and symptom differentiation; a detailed analysis of PCP and ketamine is a separate substance-specific subject. SAMHSA's survey methodology.

Substance use, risky use, harmful use, and disorder

Substance use describes exposure or consumption. Risky use describes circumstances that increase the probability of harm, including impaired driving, unpredictable products, use in vulnerable medical or psychiatric circumstances, and combining substances. An episode of harmful use denotes an exposure associated with documented injury or damage. A harmful pattern implies recurrent or persistent harm under the relevant classification. A use disorder is a diagnostic construct defined by its specified set of symptoms and consequences, rather than by disapproval of the drug or by the intensity of an isolated experience. WHO ICD-11 clinical requirements.

The distinction matters because prevention, emergency treatment, and longitudinal care serve different needs. Someone seeking help after frightening perceptual changes requires evaluation for intoxication, panic, delirium, psychosis, or a neurological condition. Someone whose repeated use is creating major impairment requires a structured substance-use assessment and continuing clinical follow-up. Both deserve a clear, respectful explanation of their presentation.

Diagnostic Status in DSM-5-TR and ICD-11

DSM-5-TR: other hallucinogen use disorder

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) places hallucinogen-related disorders among substance-related and addictive disorders. It distinguishes other hallucinogen use disorder from phencyclidine use disorder and from associated intoxication and substance-induced diagnoses. For other hallucinogen use disorder, clinicians assess a clinically significant problematic pattern over the specified period, normally twelve months, using the applicable DSM symptoms. Two or more qualifying criteria can support a diagnosis after substance-specific exclusions and clinical judgment. DSM severity is ordinarily described as mild for two or three criteria, moderate for four or five, and severe for six or more. DSM-5-TR diagnostic summary.

The relevant features include consuming more than intended, repeatedly failing to reduce use, devoting substantial time to obtaining or recovering from the substance, craving, impaired role fulfillment, interpersonal conflict, giving up valued activities, recurrent use in hazardous situations, and continuing despite recognized problems attributable to use. Tolerance may be part of the applicable diagnostic picture. A defined physiological withdrawal syndrome for classical hallucinogens is not an established DSM criterion, and clinicians must not treat its absence as proof that behavioral impairment is absent. Exact counting requires consulting the substance-specific DSM rules and considering whether a criterion is attributable to that substance. American Psychiatric Association; Johns Hopkins diagnostic table.

The threshold is deliberately behavioral and functional. It cannot be inferred from the number of psychedelic experiences, a positive drug screen, a preference for altered states, or a spiritual account of their meaning. Similarly, a person's use of the phrase addicted to psychedelics communicates distress but is an entry point for assessment, not the completed diagnosis.

DSM-5-TR: phencyclidine use disorder and related conditions

PCP and closely related substances warrant their own evaluation because dissociative intoxication may involve marked agitation, confusion, impaired motor control, autonomic changes, dangerous behavior, and medical complications. A PCP-related use disorder is not merely a more severe version of an LSD- or psilocybin-related disorder. The substance category determines which diagnostic criteria and associated syndromes apply. Ketamine exposure may involve overlapping dissociative effects and may also be associated with distinctive urinary tract and other medical harms with repeated nonmedical use. A comprehensive assessment therefore records the actual substance whenever it can be established instead of using hallucinogen as an undifferentiated label. NIH's overview of psychedelic and dissociative drugs.

ICD-11: harmful use and dependence

The WHO ICD-11 organizes disorders due to use of hallucinogens within category 6C49. Its clinical architecture includes an episode of harmful use, a harmful pattern of use, hallucinogen dependence, intoxication, and specific hallucinogen-induced mental or behavioral syndromes. Dependence is a relatively uncommon classification for hallucinogens, and the WHO description does not identify a characteristic hallucinogen withdrawal syndrome. The existence of a dependence code reflects that clinically important impaired control and prioritization of use may occur in some individuals. WHO ICD-11 diagnostic manual; WHO substance-use terminology.

ICD-11 dependence emphasizes impaired control, increasing priority of substance use over other activities, and physiological features when relevant. Harmful-use categories capture health damage without requiring that the dependence syndrome is present. This framework is designed to recognize meaningful harm across different patterns of psychoactive-substance exposure. When a patient receives care across health systems, a clinician may encounter DSM terminology, ICD-11 coding, or older legacy codes. Their labels should be translated through the underlying clinical facts rather than treated as exact word-for-word equivalents.

Why the classifications are different

Diagnostic manuals serve clinical communication, epidemiology, and health-system purposes. DSM-5-TR uses symptom-based use-disorder thresholds and severity specifications. ICD-11 separates harmful episodes, harmful patterns, and dependence. Each classification handles the boundaries between intoxication, ongoing impairment, and related mental conditions according to its own rules. This is particularly important for classical psychedelics because dramatic acute changes in perception and emotion do not consistently accompany repeated reinforcement or physiological withdrawal. The categories are best understood through documented impairment and the time course of a person's experience. WHO.

Symptoms and Clinical Signs

Impaired control and repeated unwanted use

A person may repeatedly plan to use less often and then find that use resumes despite a clear personal decision. They may spend increasing amounts of time arranging access, preparing for experiences, managing aftermath effects, or recovering from acute distress. Craving may arise as a psychological expectation of relief, insight, belonging, or escape from difficult emotions. Clinical interviewing examines how often this occurs, the connection to life events, and whether ordinary responsibilities are affected. The question is whether a reproducible pattern of impaired control has developed, with a clinically important effect on life. DSM-5-TR diagnostic summary.

Functional impairment and continued use despite consequences

Concerning consequences may involve missed work, reduced academic performance, repeated family conflict, impaired caregiving, unsafe behavior while intoxicated, financial disruption, or progressively narrowing interests. Other individuals may continue using a hallucinogen despite a clear temporal association with severe panic episodes or perceptual aftereffects. Clinicians must assess whether these difficulties genuinely result from the substance, whether they predate its use, and whether competing explanations are more likely. The functional standard protects patients from both overdiagnosis and underrecognition of real harms.

Craving, salience, and psychological reinforcement

Compelling anticipation of another experience may reflect a desire to repeat pleasurable effects, regulate mood, connect with a group, or respond to stress. Some people develop strong rituals around acquisition and use even when classical psychedelics display limited reinforcement in many experimental models. Subjective meaning and social context can sustain repeated behavior without a traditional withdrawal cycle. Such mechanisms are plausible clinical formulations; the presence of a ritual alone is not a diagnostic criterion. Johnson and colleagues' abuse-potential review.

Tolerance and the absence of a typical withdrawal syndrome

Pharmacological tolerance means a reduced effect with repeated exposure or the need for greater exposure to achieve an equivalent effect. Some classical serotonergic psychedelics produce relatively rapid tolerance, plausibly associated with receptor adaptations, yet tolerance is neither universal nor sufficient to establish a disorder. As a separate concept, physical dependence refers to physiological adaptation that may produce a recognizable withdrawal syndrome when exposure falls. A characteristic potentially life-threatening withdrawal syndrome, such as those seen with severe alcohol or benzodiazepine dependence, is not established for classic hallucinogens. Patients using multiple drugs may nonetheless face dangerous alcohol or sedative withdrawal, making a full medication and substance inventory essential. Johns Hopkins diagnostic reference; WHO.

Emotional, perceptual, and behavioral symptoms

While intoxicated, people may experience vivid visual distortions, intensified colors, altered sound, unusual thought associations, fear, depersonalization, and shifts in perception of time. Intense anxiety, agitation, confusion, or suspiciousness may become clinically urgent. These are signs of an acute drug effect or related syndrome; they are not by themselves symptoms proving a long-term use disorder. Persistent perceptual symptoms or a sustained psychotic episode require separate examination after the immediate intoxication phase. NIDA; NIH Health.

Can LSD or Psilocybin Cause Addiction?

The scientific answer depends on the meaning of addiction, the drug involved, and the outcome measured. Classic serotonergic psychedelics typically show lower compulsive reinforcement and dependence liability than substances such as opioids, nicotine, or cocaine in available animal models, laboratory studies, and epidemiological observations. This population-level statement does not exclude an individual diagnosis of problematic hallucinogen use. The literature is also affected by inconsistent definitions, self-selected study participants, limited longitudinal research, and grouping unlike compounds under a single survey label. Johnson and colleagues; NIDA.

The presence of legal restrictions, an intense perceptual reaction, or a favorable personal account does not establish dependence potential. Conversely, the possibility of therapeutic research does not show that unrestricted nonmedical use is without risk. Drug effects, use patterns, product identity, family and psychiatric history, and clinical setting all influence consequences. Addiction liability is one dimension of risk; acute injury, psychological destabilization, and persisting perceptual symptoms are other dimensions that deserve independent assessment.

What prevalence figures can and cannot show

In the 2023 US National Survey on Drug Use and Health, approximately 8.8 million people aged twelve or older reported hallucinogen use in the prior year. The survey's broad hallucinogen category includes substances with different pharmacology, including LSD, psilocybin, MDMA, PCP, ketamine, and others. That number is a past-year use estimate, not a count of people meeting criteria for hallucinogen use disorder and not a rate of psychedelic dependence. Estimates for one substance, age group, year, or outcome should not be generalized to all psychedelic experiences. SAMHSA 2023 NSDUH report.

Studies that recruit healthy volunteers for monitored psychedelic administration cannot estimate the safety of unknown products, uncontrolled environments, repeated high-frequency use, or people with significant psychiatric vulnerabilities. Likewise, retrospective survey associations do not by themselves prove that psychedelics caused the later event. Reliable interpretation requires attention to selection, confounding, measurement, and timing.

Neurobiological and Psychological Mechanisms

Serotonin 5-HT2A signaling and acute perceptual effects

LSD, psilocybin-derived psilocin, DMT, and mescaline are pharmacologically distinct but share important activity at serotonin 5-HT2A receptors. Receptor activation affects cortical signaling and network dynamics implicated in sensory integration, meaning attribution, and self-referential experience. These effects help explain the characteristic transient alterations in perception and cognition. Specific neural signatures are active research topics, and a single receptor pathway is not a complete account of every psychedelic experience or later behavior. Nichols, Pharmacological Reviews; Drewko and colleagues, Molecular Psychiatry.

Learning, expectations, and context

Expectations about a substance and the surrounding environment can alter emotional responses. Repeated use may become linked with social belonging, relief from uncertainty, avoidance of distress, or anticipated transformative experience. Through associative learning, reminders of particular places, friendships, or emotional states may become cues for renewed use. These mechanisms are compatible with broad models of substance-use behavior but remain less directly studied in hallucinogen use disorder than in alcohol, opioid, or stimulant disorders. Clinical inference must therefore remain proportionate to the available evidence. NIDA.

Individual susceptibility and co-occurring conditions

Clinical outcomes also depend on developmental stage, psychiatric vulnerability, trauma exposure, sleep loss, concurrent substances, medication interactions, and the reliability of the product's identity. Anxiety may precede use, intensify during intoxication, or emerge as part of an independently diagnosable condition. A person may use psychedelics as a coping strategy while simultaneously experiencing depression, anxiety, or another substance-use disorder. The temporal sequence and independent persistence of symptoms determine the diagnostic formulation. Related clinical considerations are covered in Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity.

Acute Intoxication, Overdose, and Toxic Syndromes

Acute psychedelic intoxication

Hallucinogen intoxication is an acute syndrome linked to exposure, typically with marked changes in perception, mood, cognition, and sometimes autonomic signs such as increased heart rate or blood pressure. A person may remain aware that the experience is drug-related, yet severe anxiety or loss of orientation can impair safety. Evaluation addresses vital signs, temperature, hydration, level of consciousness, possible trauma, medications, and the likelihood of additional substances. An individual experiencing a frightening perceptual state requires calm medical assessment and protection from accidental injury, rather than an assumption that every symptom is psychiatric. NIH Health.

Medical emergencies and unknown substances

Emergency evaluation is warranted for seizures, loss of consciousness, breathing difficulty, chest pain, dangerously elevated body temperature, severe agitation, marked confusion, new neurological deficits, serious injury, or persistent behavior creating immediate danger. Severe suicidal thoughts or behavior, apparent psychosis with inability to maintain safety, and rapidly worsening symptoms also justify urgent care. Street products sold under familiar psychedelic names can contain other compounds. A clinician must consider stimulants, potent synthetic hallucinogens, serotonergic toxicity, anticholinergic poisoning, dissociatives, and combinations rather than assuming that the reported substance is chemically verified. NIH Health.

Serotonin toxicity and medication interactions

Some serotonergic drugs and combinations can produce a potentially life-threatening toxic syndrome involving altered mental status, neuromuscular abnormalities, and autonomic instability. This presentation must be distinguished from an expected transient perceptual change. The risk depends on the actual agent and co-exposures; labels such as hallucinogen do not determine pharmacological interactions. People receiving antidepressants, monoamine oxidase inhibitors, stimulants, or other psychoactive drugs should discuss substance exposure honestly with the treating clinician. Medical assessment is preferable to self-directed medication changes during an acute reaction.

Why overdose does not always resemble opioid overdose

The term overdose describes a toxic exposure or medical emergency, not one universal physiological pathway. Many classic psychedelic crises are dominated by psychological distress, impaired judgment, autonomic effects, or injury. An opioid-contaminated product or combination involving opioids may additionally cause slowed or absent breathing and require the emergency response appropriate to opioid overdose, including naloxone where indicated. A substance of uncertain identity can produce overlapping syndromes. Emergency responders should be told about suspected exposures as accurately as possible. NIH Health.

Hallucinogen-Induced Psychosis, Anxiety, and Mood Symptoms

Severe anxiety during intoxication may include panic, fear of death, frightening interpretations of sensory changes, or transient paranoia. Symptoms can diminish as the acute effects resolve. A hallucinogen-induced psychotic disorder is considered when psychotic symptoms emerge in a clinically meaningful temporal relationship to substance exposure and the overall picture meets applicable criteria. The differential diagnosis includes intoxication, delirium, a primary psychotic disorder, mania, sleep deprivation, a medical or neurological illness, and other drugs. Persistence beyond the expected intoxication period increases the need for specialist evaluation. WHO ICD-11 clinical descriptions.

The evidence base for psychosis and mania following psychedelics requires careful interpretation. Monitored clinical trials commonly exclude people considered at elevated psychiatric risk and provide preparation, supervision, and follow-up. A 2024 systematic review and meta-analysis of adverse events in clinical and research settings describes events under those selected conditions; it cannot establish a population-wide absence of risk. Case reports demonstrate possible serious events but are poorly suited for estimating the probability of a reaction in all users. Hinkle and colleagues, JAMA Psychiatry.

The coexistence of a use disorder and a psychotic disorder should be evaluated on independent timelines. Substance exposure may worsen symptoms in a susceptible person, coexist with a primary disorder, or be inaccurately blamed for symptoms arising from another cause. A full clinical formulation includes prior episodes, family history when available, symptoms during sustained nonuse, functional trajectory, and other exposures. Ongoing psychosis, suicidal risk, or inability to care for basic needs warrants prompt specialist or emergency assessment.

Hallucinogen Persisting Perception Disorder (HPPD)

HPPD is a distinct diagnostic condition in which perceptual disturbances experienced during prior substance exposure persist or recur after the expected acute drug effects have ended and cause clinically meaningful distress or impairment. Reports include afterimages, trailing visual phenomena, intensified colors, halos, visual snow-like experiences, geometric images, or apparent movement of stationary objects. Such symptoms can also occur in migraine, ophthalmic disease, neurological disorders, medication effects, and other psychiatric conditions; the history must support the diagnosis and exclude more appropriate explanations. Neven and Blom systematic review; Doyle and colleagues scoping review.

HPPD and ordinary flashbacks

A brief, non-distressing recurrence of an unusual sensory impression is not automatically HPPD. A clinical diagnosis requires attention to symptom quality, timing, functional burden, differential diagnosis, and current substance use. The historical term flashback is sometimes used loosely for many phenomena, making it less precise than the formal syndrome. Visual symptoms described as HPPD may begin soon after an experience or become prominent later. Their persistence should lead to clinical rather than self-diagnosed conclusions.

What the evidence says about treatment

The 2025 systematic review by Neven and Blom identified 31 studies involving 87 individuals receiving medications for HPPD. Much of the evidence consisted of case reports and small observational studies with diverse drugs and inconsistent follow-up. Individual reports of improvement cannot prove comparative efficacy, and a universally established medication regimen has not emerged. Treatment decisions depend on specialist assessment, the full diagnostic picture, co-occurring conditions, and potential medication harms. This literature concerns HPPD, not evidence-based pharmacotherapy for hallucinogen use disorder itself. Neven and Blom, Harvard Review of Psychiatry.

Clinical Screening and Diagnostic Assessment

Screening asks whether fuller assessment is needed

Screening involves brief, structured questions about exposure, frequency, context, negative consequences, and other substance use. A positive screen signals the need for further evaluation and does not establish a hallucinogen-related diagnosis. Widely used general substance-use screening tools can open a conversation, but a score cannot substitute for substance-specific clinical judgment. Screening should invite accurate disclosure and avoid treating lawful status, moral disapproval, or unusual cultural practice as medical symptoms. McNeely and colleagues, Substance Use Screening, Risk Assessment, and Use Disorder Diagnosis in Adults.

The clinical interview

A thorough history specifies the names and possible identities of substances used; route, frequency, typical context, duration, and latest use; unwanted changes in control; functional consequences; effects during and after intoxication; and the patient's own concerns. Clinicians should ask about alcohol, benzodiazepines, opioids, cannabis, stimulants, prescription drugs, supplements, and other compounds. The evaluation should include sleep, mood, suicidality when clinically indicated, psychotic symptoms, trauma, cognitive status, and medical history. The interview is ideally collaborative and person-centered, with attention to confidentiality and immediate safety.

Laboratory tests and toxicology limitations

No routine blood test, brain scan, or screening questionnaire independently establishes hallucinogen use disorder. Standard urine drug screens may fail to detect many psychedelic drugs and may have limited windows of detection or cross-reactivity. A negative result cannot reliably exclude past use, and a positive result documents exposure more directly than impairment or disorder. Where acute toxicity is suspected, laboratory and other investigations are directed by the medical presentation. If the drug identity is disputed or essential to care, clinicians may consider appropriate confirmatory testing, acknowledging that such tests may not be routinely available.

Applying criteria and assessing severity

Diagnosis requires a time-linked account of qualifying symptoms and a clinical judgment that the pattern is significant, persistent where required, and best explained by the identified substance. Clinicians should document why each criterion is met, the relevant timeframe, substances involved, and impact on functioning. Severity labels describe the number of qualifying DSM criteria; they do not automatically express overdose danger or the need for a particular setting of care. High acute risk can exist without a use disorder, and severe functional impairment can exist without a dramatic overdose. DSM-5-TR criteria summary.

Differential Diagnosis and Comorbidity

The assessment must distinguish other hallucinogen use disorder from an isolated acute intoxication, substance-induced anxiety or psychosis, HPPD, bipolar-spectrum illness, a primary psychotic disorder, neurological disease, and medical toxicology emergencies. An anxiety disorder may predate psychedelic use, arise during the acute episode, or persist separately. Visual changes can be caused by migraine aura, seizure phenomena, retinal disorders, or medication effects. In each case, the diagnosis rests on the temporal sequence, the broader symptom pattern, examination, and context rather than a single remembered drug experience.

Multiple substance exposures can obscure causation. Cannabis, alcohol, MDMA, stimulants, or dissociatives may contribute substantially to psychiatric and autonomic symptoms. Someone who uses classical psychedelics occasionally but has compulsive stimulant use may require primary care for stimulant use disorder and a separate explanation of psychedelic-related events. A clinical interview should therefore avoid turning the umbrella word hallucinogen into an all-purpose diagnosis. The broader approach is explained in What Is a Dual Diagnosis? Substance Use and Co-Occurring Mental Disorders.

Evidence-Based Clinical Management

Immediate safety comes first

When someone presents acutely, clinicians prioritize medical stability, evaluation of possible toxic co-exposures, management of agitation or severe anxiety within an appropriate care setting, and assessment for injury or suicide risk. The appropriate environment depends on vital signs, orientation, behavior, and the potential for sudden deterioration. Supportive clinical measures and observation are frequently relevant to uncomplicated intoxication, while significant toxicity requires emergency medicine expertise. There is no safe general-purpose home protocol for managing an unknown compound or mixed overdose.

Treatment for a persistent use disorder

For a verified hallucinogen use disorder, a therapeutic plan begins with a shared account of what the individual wants to change and what risks are present. Motivational interviewing can help explore ambivalence and personal reasons for change. Cognitive behavioral approaches can examine substance-use cues, expectations, coping strategies, avoidance behavior, and the practical circumstances of repeated use. Care may include support for sleep, mood, family communication, social stability, and co-occurring substance-use disorders. These approaches draw on the broader substance-use-treatment literature; direct randomized efficacy trials focused specifically on classic hallucinogen use disorder remain limited. It would therefore overstate the evidence to assign these treatments a substance-specific effect size based on trials involving other drugs. WHO and UNODC international treatment standards.

Clinical support can be brief or longitudinal depending on persistence, impairment, motivation, co-occurring disorders, and safety. For some people, psychoeducation and follow-up are sufficient. Others benefit from structured outpatient therapy, integrated psychiatric care, or a higher level of monitoring when risk requires it. Choosing a setting should reflect multidimensional assessment rather than a label alone. The related article Addiction Severity and Level of Care: How Treatment Needs Are Assessed explains this distinction.

Medication evidence and its limits

There is no widely established, hallucinogen-use-disorder-specific medication regimen supported by large, replicated clinical trials. Pharmacotherapy may be appropriate for a separately diagnosed depressive, anxiety, psychotic, or other medical condition after individualized assessment. Medications used in a supervised emergency department address the acute syndrome; they do not automatically treat the longer-term behavioral use disorder. Likewise, medication reports for HPPD cannot be generalized to a patient whose primary problem is compulsive psychedelic use. Evidence strength and the identity of the treated condition should be explicit whenever medication is discussed.

Harm reduction and practical prevention

Clinical prevention emphasizes avoiding impaired driving and other hazardous activities during intoxication, reducing exposure to unknown products, recognizing the dangers of mixing drugs, responding promptly to severe symptoms, and discussing psychiatric or medication vulnerabilities with qualified clinicians. A person who has experienced psychosis, mania, severe panic, or persistent perceptual symptoms after exposure warrants focused medical advice about subsequent risk. For individuals with a diagnosed use disorder, reducing hazardous situations and improving access to care can be immediate meaningful goals even when long-term objectives are still being negotiated. NIH Health; WHO and UNODC.

Recovery and follow-up

Recovery can involve sustained reduction or cessation of problematic use, improved functioning, restoration of relationships and roles, management of other psychiatric conditions, and confidence in everyday coping. Some people define success through abstinence; others initially focus on risk reduction and clinical stability. Clinicians can revisit the diagnosis over time as symptoms and functioning change, and document remission only under the applicable diagnostic criteria. Recurrence of substance use, return of a use disorder, and renewed HPPD symptoms are different events that require precise descriptions. Longitudinal outcomes specifically for classical hallucinogen use disorder have been studied less extensively than outcomes for several more prevalent substance-use disorders.

Special Populations and Clinical Context

Adolescents and young adults

Adolescents and young adults may face substance-related risks in the context of developing executive functions, school pressures, peer networks, and emerging psychiatric illness. Family circumstances, trauma exposure, and other drug use shape assessment and care. Clinicians should use age-appropriate confidentiality practices, evaluate immediate safety, and avoid extrapolating from trials conducted in carefully screened adults. The relatively high survey rate of use among young adults does not indicate that most users have a disorder. SAMHSA NSDUH.

Pregnancy and reproductive care

Substance exposure during pregnancy requires individualized discussion of possible maternal and fetal risks, other substances, medications, and the limitations of available human outcome data. Evidence for many psychedelic exposures during pregnancy is sparse, and a low measured rate of addiction does not imply reproductive safety. Acute psychiatric or medical complications should be assessed by appropriate clinicians. Screening and support work best when they encourage open disclosure and preserve access to prenatal care.

People with psychosis, bipolar disorder, or major psychiatric vulnerability

A personal history of mania, psychosis, severe mood instability, or a strong family history of certain disorders may materially change the clinical risk assessment. The ability to maintain safety during an acute perceptual disturbance can also be compromised by active psychiatric symptoms. Controlled psychedelic trials frequently exclude higher-risk participants, leaving important evidence gaps for these populations. Coordinated substance-use, psychiatric, and medical evaluation is indicated when symptoms interact. Hinkle and colleagues.

Polysubstance use and medication exposure

The combination of psychedelics with alcohol, sedatives, stimulants, opioids, or other serotonergic agents may change the clinical syndrome and level of danger. Someone taking benzodiazepines or drinking heavily every day also requires assessment for potentially dangerous withdrawal from those substances; the absence of classic psychedelic withdrawal provides no reassurance about alcohol or benzodiazepine cessation. Toxicity, psychiatric destabilization, and drug interaction concerns should be handled according to the actual substances involved. This makes accurate exposure history central to a safe diagnosis.

Psychedelic-Assisted Therapy Is a Separate Research Question

Researchers are investigating psychedelic-assisted interventions for selected psychiatric and substance-use conditions. These programs typically involve participant selection, controlled drug administration, professional supervision, structured psychotherapy or support, and follow-up. They study an intervention under specific clinical conditions. They do not test whether repeated nonmedical psychedelic use prevents addiction, and they do not establish efficacy for treating hallucinogen use disorder itself. Meshkat and colleagues' 2025 systematic review.

A 2025 systematic review of psilocybin for substance-use disorders found sixteen published studies across alcohol, tobacco, and several other disorders, with many observational or open-label designs and a small number of randomized comparisons. Early signals of benefit for alcohol and tobacco outcomes were judged preliminary by the reviewers. Research involving a monitored psychedelic intervention for alcohol use disorder cannot be transferred directly to unsupervised recreational use, to hallucinogen dependence, or to people excluded from the studies. Separate reviews have likewise emphasized methodological quality, small samples, and heterogeneity of intervention types. Meshkat and colleagues; Piper and colleagues.

What Is Established, Preliminary, Limited, or Contested?

Established diagnostic practice recognizes hallucinogen-related syndromes and supports systematic evaluation of impaired control, harmful consequences, acute toxic effects, and alternative explanations. It is also established that classical psychedelics differ pharmacologically from dissociatives and from drugs with prominent physiological withdrawal. Classification manuals and official clinical resources supply the basis for these distinctions. APA; WHO.

Preliminary findings include potentially beneficial psychedelic-assisted interventions for selected non-hallucinogen substance-use disorders, and proposed neurobiological mechanisms connecting psychedelic effects to longer-term psychological changes. The trials are heterogeneous and their participants selectively screened. Limited evidence concerns the prevalence, longitudinal course, and optimal treatment of classic hallucinogen use disorder, as well as comparative medications for HPPD. Contested or unresolved questions include the frequency of rare persistent adverse outcomes after different exposures, the precise causal roles of individual vulnerability and concurrent drugs, and how emerging compounds should be grouped for risk evaluation. Hinkle and colleagues; Neven and Blom; Meshkat and colleagues.

Frequently Asked Questions

Is hallucinogen use disorder a real diagnosis?

Yes. DSM-5-TR recognizes other hallucinogen use disorder and a separate PCP use disorder, while ICD-11 describes harmful hallucinogen use and hallucinogen dependence. The proper diagnosis depends on the actual substance and a clinician's assessment of qualifying symptoms, impairment, and diagnostic exclusions. APA; WHO.

Does occasional use mean a person has an addiction?

No. Frequency is relevant clinical information, but the diagnosis requires specific symptoms and clinically significant consequences. An infrequent exposure can still produce an emergency or persistent adverse effect, which may require care under a different diagnosis. DSM-5-TR diagnostic reference.

Can a person develop tolerance without hallucinogen use disorder?

Yes. Tolerance is a physiological adaptation that can occur without the broader pattern of impairment required for a use disorder. Tolerance, physical dependence, withdrawal, and compulsive use are separate concepts. Johns Hopkins diagnostic table.

Is there a withdrawal syndrome after stopping LSD or psilocybin?

A characteristic physiological withdrawal syndrome is not established for classical hallucinogens. Symptoms following cessation deserve assessment for co-occurring psychiatric conditions, other drug withdrawal, sleep disruption, or unrelated illness. Dangerous alcohol and benzodiazepine withdrawal remain important when those substances are involved. WHO ICD-11.

Is HPPD the same as hallucinogen use disorder?

No. HPPD concerns distressing persisting or recurrent perceptual disturbances after exposure and has its own diagnostic considerations. Hallucinogen use disorder concerns a problematic pattern of consumption and associated impaired control or consequences. They can coexist but are assessed separately. Neven and Blom.

What if symptoms continue after the drug should have worn off?

Persistent hallucinations, paranoia, disorientation, severe anxiety, new visual disturbances, or functional decline warrant clinical evaluation. Severe confusion, suicidal behavior, seizures, breathing difficulty, chest pain, or major neurological symptoms warrant emergency assessment. Clinicians distinguish HPPD, substance-induced syndromes, neurological illness, and primary psychiatric conditions according to the presentation.

Are there approved medications specifically for hallucinogen use disorder?

A medication with a replicated evidence base establishing it as standard treatment specifically for hallucinogen use disorder has not been identified. Care generally emphasizes individualized psychological and behavioral support, risk management, assessment of co-occurring conditions, and follow-up. Emergency medications and treatments for a separately diagnosed condition address different clinical targets.

Can clinical psychedelic therapy prove psychedelics are harmless?

No. Clinical trials evaluate selected treatments under defined safety protocols, with exclusions and monitoring. Their findings do not directly estimate risk in unsupervised settings or for people with different psychiatric histories. Hinkle and colleagues; Meshkat and colleagues.

Clinical Interpretation and Practical Conclusion

Hallucinogen use disorder is best understood through demonstrable impairment and accurate identification of the substance involved. The central clinical distinctions are between exposure, risky behavior, harmful patterns, ongoing impaired control, acute intoxication, drug-induced mental syndromes, and persisting perceptual effects. These distinctions protect patients from inappropriate labels while allowing severe or continuing problems to be recognized promptly. Responsible care relies on collaborative history-taking, evaluation for co-occurring conditions, evidence-calibrated treatment, and emergency assessment when acute danger is present. The science supports a differentiated account of psychedelic drugs: risk is real and substance-specific, diagnostic categories exist, and questions about optimal treatment require continued rigorous research.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — scientific foundations, classification, treatment and recovery across substance types.

Substance Use Disorder: Symptoms, Diagnosis, and Treatment — the general clinical framework for impaired control, diagnostic symptoms and treatment planning.

Substance Use Disorder vs Substance Misuse: Clinical and Everyday Terms — terminology and the boundary between problematic use and diagnosed disorder.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — differential assessment when anxiety and substance use interact.

What Is a Dual Diagnosis? Substance Use and Co-Occurring Mental Disorders — integrated evaluation of substance use and co-occurring mental health problems.

How Addiction Affects the Brain: Reward, Learning, and Control — mechanisms of reward, learning and control in broader addiction science.

Substance Use Disorders and Suicide Risk: Evidence, Assessment, and Safety — clinically focused suicide-risk assessment and safety planning.

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR). APA diagnostic manual information.

Doyle, M. A., et al. (2022). Hallucinogen persisting perceptual disorder: A scoping review covering frequency, risk factors, prevention, and treatment. Expert Opinion on Drug Safety. PubMed.

Drewko, A. J., Habets, R. L. P., and Brunt, T. M. (2025). Above the threshold, beyond the trip: The role of the 5-HT2A receptor in psychedelic-induced neuroplasticity and antidepressant effects. Molecular Psychiatry. Publisher.

Hinkle, J. T., Graziosi, M., Nayak, S. M., and Yaden, D. B. (2024). Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. JAMA Psychiatry, 81(12), 1225–1235. DOI: 10.1001/jamapsychiatry.2024.2546.

Johnson, M. W., Griffiths, R. R., Hendricks, P. S., and Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143–166. DOI: 10.1016/j.neuropharm.2018.05.012.

McNeely, J., Hamilton, L. K., Whitley, S. D., et al. (2024). Substance Use Screening, Risk Assessment, and Use Disorder Diagnosis in Adults. Johns Hopkins University. NCBI Bookshelf.

Meshkat, S., et al. (2025). Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neuroscience and Biobehavioral Reviews, 173, 106163. DOI: 10.1016/j.neubiorev.2025.106163.

National Institute on Drug Abuse. (n.d.). Psychedelic and Dissociative Drugs. National Institutes of Health. Official resource.

National Institutes of Health. (n.d.). Psychedelic and Dissociative Drugs. NIH Health.

Neven, A., and Blom, J. D. (2025). Pharmacological treatment of hallucinogen persisting perception disorder (HPPD): A systematic review. Harvard Review of Psychiatry, 33(5), 264–275. DOI: 10.1097/HRP.0000000000000439.

Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. DOI: 10.1124/pr.115.011478.

Piper, T., Small, F., et al. (2025). Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. Addiction. DOI: 10.1111/add.16762.

Substance Abuse and Mental Health Services Administration. (2024). Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. Official report.

World Health Organization. (2024). Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disorders. Official WHO publication.

World Health Organization and United Nations Office on Drugs and Crime. (2020). International Standards for the Treatment of Drug Use Disorders. Official WHO publication.